Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
Why Freedom of Expression Must Not Become a Right to Harass or Intimidate 
The Law Bytes Podcast, Episode 251: Jennifer Pybus on the Debate Over Canadian Digital Sovereignty 
Reversing the Reversal?: Government Puts Privacy Invasive Lawful Access Back on the Agenda 
Canadian Government Introduces New Stablecoin Act as Part of Budget Implementation Legislation 
The Law Bytes Podcast, Episode 250: Wikimedia’s Jan Gerlach on the Risks and Challenges with Digital Policy Reform
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?